CT1192 / CARsgen - LARVOL DELTA

Safety, Efficacy and Cellular Metabolic Dynamics of ct1192 in Patients With Moderate to Severe Refractory SLE (clinicaltrials.gov) - P1 | N=12 | Recruiting | Sponsor: Union Hospital, Tongji Medical College, Huazhong University of Science and Technology | Not yet recruiting ➔ Recruiting

Enrollment open • IO biomarker • Immunology • Inflammatory Arthritis • Lupus • Systemic Lupus Erythematosus

The Safety, Efficacy, and Cellular Metabolic Kinetics of CT1192 in Treating Patients With Anti Neutrophil Cytoplasmic Antibody Associated Vasculitis (clinicaltrials.gov) - P1 | N=12 | Not yet recruiting | Sponsor: Wuhan Union Hospital, China

IO biomarker • New P1 trial • ANCA Vasculitis • Vasculitis

Safety, Efficacy and Cellular Metabolic Dynamics of ct1192 in Patients With Moderate to Severe Refractory SLE (clinicaltrials.gov) - P1 | N=12 | Not yet recruiting | Sponsor: Wuhan Union Hospital, China

IO biomarker • New P1 trial • Immunology • Inflammatory Arthritis • Lupus • Systemic Lupus Erythematosus